Bartter Syndrome Treatment Market Insight and Trends 2027

 Bartter Syndrome Treatment: Introduction

• Bartter syndrome is a group of genetic diseases known to cause specific defects in kidney functioning. It is caused by the alteration in one of the several genes, including SLC12A1 gene, KCNJ1 gene, CLCNKB gene, BSND gene, and MAGED2 gene. These defects affect the kidney’s salt reabsorption ability and leads to fluid and electrolyte imbalances in the body. The major electrolytes affected include mineral salts such as magnesium, chloride, sodium, potassium, and calcium.
• The three primary forms of Bartter syndrome are antenatal Bartter syndrome, classic Bartter syndrome, and Gitelman syndrome. Antenatal Bartter syndrome usually starts before birth and is a life-threatening condition. Classic Bartter syndrome usually starts after birth, leading to developmental delays affecting overall growth. Gitelman syndrome is a sub-type of Bartter syndrome, which usually happens from the age of six to adulthood.
• The symptoms of the disease vary for all individuals and among individuals with the same condition. However, the common symptoms include general feeling of being unwell, frequent urination, slower than normal developmental growth, severe thirst, increasing cravings for salt, cramping and muscular weakness, and constipation.
• The various forms of Bartter syndrome have varied manifestations depending on the underlying genetic defect, including hypocalcemia, nephrocalcinosis, and hearing loss

Request For Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74158

Key Drivers of Global Bartter Syndrome Treatment Market

• Rise in focus on genetic testing during pregnancy is projected to increase the demand for Bartter syndrome treatment. Additionally, identification of dominant carriers for the disease and rise in levels of genetic counselling drive demand for Bartter syndrome treatments. This in turn contributes to the growth of the global Bartter syndrome treatment market.
• Continuous investment in research & development on the diagnosis and treatment of Bartter syndrome is anticipated to fuel the growth of the global Bartter syndrome treatment market
• High investments by key players and initiatives by governments for research & development on the treatment of Bartter syndrome are expected to propel the global Bartter syndrome treatment market. According to the National Organization for Rare Disorders, Inc. (NORD), Bartter syndrome is quite rare and occurs in one in 100,000 people in the general population.
• However, lack of awareness among people owing to its rarity of occurrence is likely to hamper the growth of the global Bartter syndrome treatment market during the forecast period.

Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=74158

Potassium & Magnesium Supplements to be Most Attractive Segment

• In terms of treatment, the global Bartter syndrome treatment market can be classified into non-steroidal anti-inflammatory drugs (NSAIDS), diuretics, potassium & magnesium supplements, RAAS inhibitors, and others
• The RAAS inhibitors segment can be split into aldosterone antagonists, angiotensin II receptor blockers, and angiotensin-converting enzyme (ACE) inhibitors
• Potassium & magnesium supplements is projected to be the most attractive segment of the global Bartter syndrome treatment market during the forecast period, as it is considered standard treatment therapy for Bartter syndrome

North America to Dominate Global Bartter Syndrome Treatment Market

• In terms of region, the global Bartter syndrome treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the global Bartter syndrome treatment market during the forecast period due to rise in awareness among people about prenatal genetic testing, increase in the number of prenatal genetic tests performed, well-established health care infrastructure, and presence of leading players. The exact prevalence of the disease cannot be ascertained; however, the prevalence of Bartter syndrome in Costa Rica is estimated to be around 1.2 cases per 100,000 live births.
• Europe was the second largest market for Bartter syndrome treatments in 2020, followed by Asia Pacific
• Asia Pacific is expected to be the fastest growing market for Bartter syndrome treatment, followed by Latin America and Middle East & Africa. Improving health care facilities, rise in awareness about the screening of this rare disease, and investments in clinical trials are likely to augment the Bartter syndrome treatment market in Asia Pacific. Growth of the Bartter syndrome treatment market in the region can be attributed to higher prevalence of Gitelman syndrome, a subtype of Bartter syndrome, in countries in Asia compared to other countries. Late onset of type 4 Bartter syndrome has been reported in Japan, contributing to the rise in demand for treatment of Bartter syndrome treatments. This boosts the growth of the Bartter syndrome treatment market in the region.

Pre Book A Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=74158&ltype=S

Key Players Operating in Global Bartter Syndrome Treatment Market

Key players operating in the global Bartter syndrome treatment market are:

• B. Braun Melsungen AG
• Alcon
• Pfizer, Inc.
• Perrigo Company plc
• Mylan N.V.
• Par Pharmaceutical
• Apotex, Inc.
• Ajanta Pharma
• Azurity Pharmaceuticals, Inc.
• Bausch Health
• Merck & Co., Inc.
• Almatica Pharma LLC
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Abbott Laboratories

More Trending Reports by Transparency Market Research –

• Medical Sensors Market: https://www.biospace.com/article/medical-sensors-market-to-expand-at-a-cagr-of-9-9-percent-from-2018-to-2026-rising-application-in-different-medical-areas-benefiting-industry-growth/
• 3D Bioprinting Market: https://www.biospace.com/article/3d-bioprinting-market-a-new-dawn-of-technology-promises-robust-growth/

About Us

 

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/